Celltrion’s biosimilar ‘Remsima’ cruising European market
The world’s first biosimilar antibody developed by Celltrion, Remsima, has exceeded 70% in the European market share.
According to Celltrion, the Remsima’s market share growth rate in the last 1st quarter’s entire infliximab market was analyzed at 73% which was significantly increased from the 2...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
